-+ 0.00%
-+ 0.00%
-+ 0.00%
Ascentage Pharma Presents Nine Ongoing Global Registrational Trials in Corporate Overview
Share
Listen to the news
Ascentage Pharma Presents Nine Ongoing Global Registrational Trials in Corporate Overview
  • Ascentage Pharma reported $41.6 million in product sales for the first half of 2026 from two marketed products.
  • Cash totaled $279.4 million as of June 30, 2026.
  • Nine global registrational trials are ongoing, including four FDA-cleared Phase III trials.
  • Lisaftoclax's GLORA-4 Phase III trial targets frontline higher-risk MDS, with complete response and overall survival as dual primary endpoints.
  • The China commercial team exceeds 300 employees, with plans to reach about 400 sales representatives covering approximately 80% of prescribers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending